The clinical, molecular, and pathological characterisation of a family with two cases of lethal perinatal type 2 Gaucher disease

Ellen Sidransky, Nahid Tayebi, Barbara K Stubblefield, William Eliason, Angelina Klineburgess, Gian-Paolo Pizzolato, Jeremiah N Cox, Josiane Porta, Armand Bottani, Celia D DeLozier-Blanchet

Abstract
It has recently been emphasised that a subset of patients with type 2 Gaucher disease die in the neonatal period. This report describes an Afghani family with two conceptuses having severe, prenatally detected Gaucher disease. Mutational analysis showed that the family carried a known complex allele which included mutations at amino acids L444P, A456P, and V460V. Although glucocerebrosidase RNA was present, an affected fetus had virtually no glucocerebrosidase cross-reactive material on western analyses. The severe clinical course and pathology observed in these patients resemble that of the null allele Gaucher mouse, and suggest that the absence of glucocerebrosidase activity results in early death. (J Med Genet 1996;33:132-136)

Key words: Gaucher disease; hydrops fetalis; glucocerebrosidase.

Until recently type 2 (acute neuronopathic) Gaucher disease was considered stereotypic in presentation, with neurological deterioration and death by the age of 2 to 3 years. However, the generation of a null allele, knock-out Gaucher mouse led to increased recognition of type 2 patients with a much more aggressive phenotype, who die as neonates. Although 22 neonates with type 2 Gaucher disease have been reported to our knowledge, including some who presented with hydrops fetalis or congenital ichthyosis, there has not been comprehensive analysis of glucocerebrosidase mutations, mRNA, and protein in these patients. In this report we describe the molecular characterisation of a family in which two conceptuses had severe, prenatally detected Gaucher disease.

Case reports
Although consanguinity cannot be proven, the proband’s parents both come from the same small, isolated, and inbred Afghani population. They had one healthy son. The second pregnancy (case 1) was complicated by hydramnios developing between 27 and 30 weeks of pregnancy. Prenatal ultrasound detected severe hydrops fetalis with bilateral hydrothorax and fetal hypokinesia with multiple joint contractures. Since fetal blood sampling indicated thrombocytopenia and abnormal liver enzymes, labour was induced at 33 weeks’ gestation. A 1970 g male child (fig 1) measuring 40 cm in length was delivered by caesarean section. He exhibited joint contractures, hepatosplenomegaly, pulmonary hypoplasia, muscular atrophy, and dysmorphic features that included a flattened nose with small nares and malformed ears. The skin appeared tight and shiny, especially over the face, neck, ears, thorax, and extremities. The infant died in the first hour of life. The diagnosis of type 2 Gaucher disease was based on the presence of Gaucher cells in many organs from necropsy material. The parents were subsequently confirmed by enzyme assay to be heterozygotes for Gaucher disease (mother had 62.1% and father had 66.7% of control glucocerebrosidase activity). During a third pregnancy (case 2), the prenatal diagnosis of Gaucher disease was made by enzyme assay on cultured amniocytes obtained at week 15. Neither hydrops nor joint contractures was found in the 640 g, 30 cm male fetus which was aborted at 23 weeks’ gestation.

Figure 1 Postmortem photograph of case 1.
Lethal perinatal type 2 Gaucher disease

Materials and methods

PATIENT SAMPLES
Pathological specimens were obtained at necropsy from cases 1 and 2. Amniocytes were obtained from case 2. Fibroblast lines were derived, with informed consent, from additional patients with type 1, type 2, and type 3 Gaucher disease.

MOUSE SAMPLES
Fresh tissues obtained at necropsy from neonatal type 2 Gaucher mice were immediately frozen in liquid nitrogen.

DNA PREPARATION AND SOUTHERN BLOT HYBRIDISATION
Genomic DNA was prepared from cultured cell lines from patients and controls as previously described. Human genomic DNA was digested with BamHI, electrophoresed on a 1% agarose gel, transferred to supported nitrocellulose membranes (Schleicher & Schuell, Keene NH), ultraviolet light cross linked, and then hybridised to a glucocerebrosidase cDNA probe as previously described.

Genomic DNA was also digested with SsrII and electrophoresed on a 0.6% I.D.NA™ agarose gel (FMC Rockland ME), transferred, and hybridised as described above.

RNA PREPARATION AND NORTHERN BLOT HYBRIDISATION
Total RNA was isolated from frozen cell pellets from case 2 and controls using RNAzol™B (Biotecx Houston, TX). Approximately 17 µg of total RNA from each sample was electrophoresed on a 1% agarose formaldehyde gel, transferred to a supported nitrocellulose membrane, and ultraviolet light cross linked. The membrane was prehybridised using 33 µl/cm² blot of Quik hybridisation solution (Stratagene, LaJolla, CA) at 68°C for 20 minutes, and then hybridised at 68°C for one hour using a 32P dCTP random labelled full length glucocerebrosidase cDNA probe. The blot was washed twice in a 2x SSC/0-1% (W/V) SDS at room temperature for 15 minutes and once with 0.1 x SSC/0-1% (W/V) SDS at 60°C for 30 minutes. The membrane was exposed to Kodak XAR film with an intensifying screen at -80°C overnight.

MUTATION ANALYSIS
Screening for the N370S, L444P, R463C, and 84insG mutations was performed as previously described. A 1290 bp genomic glucocerebrosidase segment, spanning exons 9 to 11, was selectively amplified using oligonucleotide primers that did not amplify the pseudogene region (forward primer 5'-AACATGAT-TCCCTATCTTC-3' from intron 8, reverse primer 5'ACCACTAGGGGAAAGTGG-3' from untranslated exon 11). This amplified DNA fragment was isolated with GeneClean II (Bio 101 LaJolla, CA) and cycle sequencing was performed according to the Taq di deoxy™ terminator kit (Applied Biosystems, Porter City, IA). The PCR product was purified using an AQUA Select-D-50 column (5' Prime, 3' Prime, Boulder, CO), vacuum dried, resuspended in loading buffer, denatured at 90°C, and loaded on a 4:75% acrylamide, 8:3 mol/l urea and 1 x TBE gel. Results were analysed using the 373 DNA Sequencing Analysis software package (Applied Biosystem, Porter City, IA).

Forward oligonucleotide primers for sequencing were 59F 5'-CACAGGGCTGA-CCTACCCA-3' (located in intron 8); 142F 5'GCAGAGTTATGGGGTGGTC-3' (located in intron 9); 878F 5'-GTGGGCTGAA-GACAGCGTTGG-3' (located in intron 10).

PROTEIN STUDIES
Cell extracts were prepared from frozen human cell pellets and from mouse tissue or fibroblasts as previously described. Glucocerebrosidase activity was measured using 4-methylumbelliferyl-β-D-glucopyranoside as substrate. Nine micrograms of protein from each sample were electrophoresed on denaturing 12% polyacrylamide gels, and the separated proteins were transferred to Immobilon P membranes. The membranes were incubated...
with rabbit polyclonal antibodies to either mouse or human glucocerebrosidase and visualised using an ECL chemiluminescence kit (Amersham, Little Chalfont, England).

**Results**

**PATHOLOGY**

Necropsy of both cases 1 and 2 indicated hepatosplenomegaly and thymic hypoplasia. Gaucher cells (fig 2) were found in the lymph nodes, thymus, spleen, liver, lungs, adrenals, bone marrow, and the central nervous system in both cases but they were less prominent in case 2. The skin histology (case 1) showed an epidermis of normal thickness with a keratinised lamellar layer (fig 3). Examination of the cerebellum and of the spinal cord showed extensive loss of Purkinje cells and lower motor neurones, respectively (fig 4). In the central nervous system, numerous PAS positive macrophages were observed, isolated and in groups, most prominently in the basal ganglia, pons, medulla, oblongata, and the motor neurones of the spinal cord. The involvement of the cerebral cortex was less extensive in case 2 (23 weeks' gestation) than in case 1 (33 weeks' gestation).

**SOUTHERN ANALYSES**

Southern analyses were performed on BamHI digested DNA from case 1, other Gaucher patients, and control samples. All samples showed identical DNA fragment patterns, having the characteristic five bands originating from both the glucocerebrosidase gene and the pseudogene. Southern analyses were also performed on SstII digested DNA from case 2 and a patient with a glucocerebrosidase fusion gene allele. The expected 48 kb band was observed in DNA from case 2. The smaller approximately 28 kb band characteristic of a fusion gene was not observed.

**MUTATION ANALYSIS**

Mutation analysis was performed on DNA from cultured amniocytes from case 2. A mutation resulting in the substitution of a proline for leucine at amino acid position 444 was detected by a Ncol digest of a PCR amplified region of the glucocerebrosidase gene. There was no normal sequence at this site. Therefore, the fetus was either homoallelic for this mutation or had only one copy of this portion of the glucocerebrosidase locus owing to a deletion in one allele. DNA analyses on the parents were not possible as they had returned to Afghanistan. Nevertheless, since the parents were from the same inbred and isolated ethnic group, it is likely that the fetus was homoallelic for this mutation.

Sequencing of a 1290 base pair PCR product spanning exons 9 to 11 amplified from this fetus confirmed that the L444P mutation was part of a complex allele resulting from a crossover event with the pseudogene. No other mutations were detected on either allele in this region. This complex allele, sometimes referred to as RecNeo, includes two additional mutations at amino acid positions A456P and V460V. These changes are normally found in the pseudogene sequence.

**NORTHERN ANALYSIS**

Northern analyses were performed with total RNA isolated from cell lines from case 2 and from controls. Using glucocerebrosidase cDNA as a probe, the expected 2·6 kb transcript was present. Using actin as a standard, the amount of RNA from case 2 was not significantly less than that obtained from the control or other patients.

**ENZYME ACTIVITY**

No glucocerebrosidase activity was observed in extracts of amniocytes from case 2. Similarly, there was no detectable glucocerebrosidase activity in tissue extracts from type 2 Gaucher.
Lethal perinatal type 2 Gaucher disease

Western analysis
Western analyses were performed on extracts from cell lines from case 2, a type 1 Gaucher patient, and a normal subject, as well as from cell lines generated from type 2 Gaucher mice and normal murine fibroblasts. No glucocerebrosidase cross reactive material was detected in extracts from case 2 or the type 2 Gaucher mice (fig 5).

Discussion
A surprising recent discovery in Gaucher disease has been the recognition of a subset of type 2 patients with pre- or perinatal onset of disease. In this report we have identified the DNA mutations in a family with 23 and 33 week fetuses having clinical, pathological, molecular, and biochemical features resembling those described in type 2 Gaucher mice.

The mutant allele in these fetuses, containing the L444P, A456P, and V460V changes, has been described primarily in the heterozygous state. All three of the observed mutations may result from an unequal homologous recombination, a fusion gene, or gene conversion. We have found only one other description of a fetus presumably homoallelic for this complex of point mutations, a prenatal lethal, with parents of Macedonian/Ashkenazi Jewish ancestry. Although that case was described as homozygous for a fusion gene which was suggested to account for some or all of the mutations in neonates, the authors used the terms “fusion gene” and “complex allele” interchangeably and provided no Southern blot or other evidence to show the actual presence of a fusion allele. Using the restriction endonuclease SsrI, which cleaves at one site upstream from the functional gene and at a second site downstream from the pseudogene, we have shown by Southern analysis of DNA from the present family that a fusion gene was not present. While the family history makes it unlikely, it is still possible that there may be a deletion of the glucocerebrosidase gene in the second allele that is not detectable on our Southern blots.

The close proximity of the human glucocerebrosidase pseudogene 16 kb downstream from the functional gene is a potential source for the generation of mutant Gaucher alleles. The patients described here appear to have suffered the result of a crossover event occurring in intron 9, an apparently critical region of the glucocerebrosidase gene, resulting in mutations at amino acid positions L444P, L456P, and V460V. In the type 2 Gaucher mouse a severe phenotype was experimentally generated by replacing intron 9 and portions of exons 9 and 10 with a neomycin cassette. It is possible that the recombination event in the cases described in this report disrupts a region with a regulatory, enhancer, or RNA stability element or another contiguous gene.

While homozygosity for this mutant allele in the two known cases appears to be predictive of very severe Gaucher disease, none of seven other neonates with this phenotype studied by our group or others share this genotype. We postulate that at least one other unknown mutation or rearrangement associated with such severe disease must exist, and thus are continuing the search for mutations in the regions flanking the glucocerebrosidase gene. Although a glucocerebrosidase transcript was present in cells from case 2, no significant glucocerebrosidase cross reactive material was detected on western blot. This suggests either that the protein was not produced, or that it was very unstable. Reports regarding stability of the protein from the complex allele RecNcil are conflicting. One group has suggested the production of a stable protein with very low enzymatic activity. Another possibility, that of reduced amounts of a very unstable protein, appears to be more likely.

Gaucher disease, particularly this severe lethal subgroup, should be considered in fetuses and neonates with hydrops fetalis, ichthyosis, or joint contractures. Both hydrops and arthrogryposis were present in the fetus diagnosed at 33 weeks' gestation, whereas they apparently had not yet developed in the fetus aborted at 23 weeks. The histological abnormality of the skin observed in case 1 substantiates that the analysis of epidermis can be particularly valuable in the diagnosis of neonatal Gaucher disease.

In both the fetuses described here and the null allele Gaucher mouse, the absence of enzyme was incompatible with long survival. Neuropathological studies of both sibs showed findings very similar to those in the null allele mouse, in that both had an apparent rostral-caudal progression of lesions with lipid ac-
cumulation varying within different brain regions. Further pathological and biochemical studies of the severely affected type 2 Gaucher mice may offer a unique opportunity to transfer insights from the murine model towards a better understanding of the pathogenesis of the disease, perhaps leading to development of new treatments for type 2 Gaucher disease.

We thank Professor N Herschkowitz for the clinical biochemical analysis as well as Drs P Estermann, M Bader, C Pag, and I Szalay for patient care. The fibroblast line from the patient with a fusion gene was kindly provided by Dr E Beuter. The murine cell lines were kindly provided by Dr C. McKinney. Helpful discussions with Drs É Ginns and B Martin are greatly appreciated. The experienced technical assistance of P Williams is gratefully acknowledged. The authors also thank K Kuhns and B Alzona for their secretarial assistance.


The clinical, molecular, and pathological characterisation of a family with two cases of lethal perinatal type 2 Gaucher disease.


doi: 10.1136/jmg.33.2.132

Updated information and services can be found at:
http://jmg.bmj.com/content/33/2/132

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/